# Rapidly progressive anti-GBM disease secondary to long-standing rheumatoid arthritis: a case report and literature review

**Authors:** Ji Li, Jing Zhang, Sheng-Guang Li, Qian Guo, Jing Xu, Lina Zhang, Yadan Zou, Ting Long, Ruohan Yu, Yanfeng Zhang

PMC · DOI: 10.3389/fimmu.2025.1661117 · 2025-10-17

## TL;DR

A rare case of anti-GBM disease in a long-term rheumatoid arthritis patient is reported, emphasizing the need for early diagnosis and careful treatment.

## Contribution

The paper presents a rare case of anti-GBM disease in RA and reviews only ten previously reported cases, highlighting its rarity.

## Key findings

- Anti-GBM disease occurred in a patient with long-standing RA without drug triggers.
- Despite treatment, the patient remained dialysis-dependent and died from complications.
- Only ten cases of RA with anti-GBM disease have been reported in the literature.

## Abstract

Long-standing rheumatoid arthritis (RA) complicated by anti–glomerular basement membrane (anti-GBM) disease is exceptionally rare.

A 71-year-old man with long-standing seropositive RA developed a rapidly progressive glomerulonephritis due to anti-GBM disease, without any known drug triggers. Despite plasmapheresis (therapeutic plasma exchange), corticosteroids, and low-dose cyclophosphamide, he remained dialysis-dependent; RA activity was subsequently controlled with tocilizumab. Complications included Stenotrophomonas maltophilia pneumonia, COVID-19 and cytomegalovirus infection, and he died of pneumonia eight months after diagnosis.

This case highlights the need for early serological testing for anti-GBM disease in RA patients with unexplained hematuria/proteinuria and for immunosuppressive therapy mindful of infection risk. Additionally, our literature review identified only ten reported cases of RA with anti-GBM disease, highlighting the rarity of this condition.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907)
- **Diseases:** rheumatoid arthritis (MONDO:0008383), glomerulonephritis (MONDO:0002462), cytomegalovirus infection (MONDO:0005132), COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** anti (MESH:D006679), COVID-19 (MESH:D000086382), RA (MESH:D001172), pneumonia (MESH:D011014), infection (MESH:D007239), Stenotrophomonas maltophilia pneumonia (MESH:C531821), glomerulonephritis (MESH:D005921), proteinuria (MESH:D011507), anti-GBM) disease (MESH:D019867), GBM disease (MESH:D005910), hematuria (MESH:D006417), cytomegalovirus infection (MESH:D003586)
- **Chemicals:** tocilizumab (MESH:C502936), cyclophosphamide (MESH:D003520)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12575370/full.md

---
Source: https://tomesphere.com/paper/PMC12575370